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accuracy of Cystatin C to detect acute kidney injury
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Feilong Wang1†, Wenzhi Pan2†, Hairong Wang1†, Yu Zhou1, Shuyun Wang1 and Shuming Pan1*Abstract
Introduction: Cystatin C (Cysc) could be affected by thyroid function both in vivo and in vitro and thereby may
have limited ability to reflect renal function. We aimed to assess the association between Cysc and thyroid hormones
as well as the effect of thyroid function on the diagnostic accuracy of Cysc to detect acute kidney injury (AKI).
Methods: A total of 446 consecutive intensive care unit (ICU) patients were screened for eligibility in this prospective
AKI observational study. Serum Cysc, thyroid hormones and serum creatinine (Scr) were measured upon entry to the
ICU. We also collected each patient's baseline characteristics including the Acute Physiology and Chronic Health
Evaluation II (APACHE-II) score. The diagnostic performance of Cysc was assessed from the area under the receiver
operator characteristic curve (AUC) in each quartile of thyroid hormone(s).
Results: A total of 114 (25.6%) patients had a clinical diagnosis of AKI upon entry to the ICU. The range of free
thyroxine (FT4) value was 4.77 to 39.57 pmol/L. Multivariate linear regression showed that age (standardized
beta = 0.128, P < 0.0001), baseline Scr level (standardized beta = 0.290, P < 0.0001), current Scr (standardized
beta = 0.453, P < 0.0001), albumin (standardized beta = −0.086, P = 0.006), and FT4 (standardized beta = 0.062,
P = 0.039) were related with Cysc. Patients were divided into four quartiles based on FT4 levels. The AUC for Cysc in
detecting AKI in each quartile were as follows: 0.712 in quartile I, 0.754 in quartile II, 0.829 in quartile III and 0.797 in
quartile IV. There was no significant difference in the AUC between any two groups (all P > 0.05). The optimal
cut-off value of Cysc for diagnosing AKI increased across FT4 quartiles (1.15 mg/L in quartile I, 1.15 mg/L in
quartile II, 1.35 mg/L in quartile III and 1.45 mg/L in quartile IV).
Conclusions: There was no significant impact of thyroid function on the diagnostic accuracy of Cysc to detect AKI in
ICU patients. However, the optimal cut-off value of Cysc to detect AKI could be affected by thyroid function.Introduction
Acute kidney injury (AKI) is a prevalent problem and
still a big challenge to both the developed and develop-
ing world [1]. About two-thirds of intensive care unit
(ICU) patients develop an episode of AKI during their
ICU stay [2]. Both short-term and long-term mortality
were higher in ICU patients with AKI than those with-
out [3-5]. Studies have found that early detection and
treatment of AKI may improve outcomes [2]. Thus,* Correspondence: pansm2010@sina.cn
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reproduction in any medium, provided the ortimely diagnosis of AKI development after renal insult is
urgent. Cystatin C (Cysc), a 13-kDa cysteine proteinase
inhibitor, is freely filtered at the glomerulus and neither
secreted nor reabsorbed by renal tubules. This physio-
logical feature makes Cysc an ideal glomerular filtration
biomarker. During the past few years, some studies have
focused on the potential value of Cysc for the diagnosis
and early detection of AKI [6-14]. However, these studies
have reported conflicting results. Some studies reported
good discrimination for Cysc in the early detection of AKI
in various patient populations [7-9,14,15], while other
studies found that Cysc had poor or moderate ability to
predict AKI [6,10-13]. Besides that, there was no consen-
sus about the appropriate cut-off value for using Cysc to
diagnose or predict AKI [6-14,16]. These inconsistenttd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of AKI in clinical practice.
Cysc is produced by all nucleated cells in the human
body at a relatively constant rate [17]. However, recent
studies found that thyroid hormones could stimulate the
production of Cysc in vitro [18,19]. Moreover, clinical
studies also found that Cysc was significantly associated
with thyroid function [20-24]. The impact of thyroid
hormones on the diagnostic value of Cysc in detecting
AKI has raised concerns in clinical practice [25-27]. To
the best of our knowledge, whether thyroid hormones
are related to the level of Cysc in ICU patients has never
been investigated. The effect of thyroid hormones on the
diagnostic accuracy and threshold of Cysc in predicting
AKI has also not been defined.
Therefore, we undertook a prospective, observational
study in a large population of unselected ICU patients to
assess: 1) the relationship between Cysc and thyroid hor-
mones; and 2) the effect of thyroid function on the diag-
nostic value of Cysc in detecting AKI.
Material and methods
Participants
This prospective study recruited consecutive patients
18 years old and older hospitalized in the ICU of Xinhua
Hospital affiliated with Shanghai Jiaotong University
School of Medicine between April 2011 and May 2012,
including medical and trauma patients. We decided a
priori to exclude patients according to the following cri-
teria: 1) past history of any thyroid diseases, such as
hyperthyroidism, hypothyroidism and thyroid tumors;
2) thyroid nodule found by physical examination when
admitted to ICU; 3) pregnancy within the previous six
months; 4) undergoing any hormone replacement therapy
except insulin use; 5) pre-existing severe renal disease
(serum creatinine (Scr) >300 umol/L) or pre-existing dia-
lysis; and 6) undergoing continuous renal replacement
therapy (CRRT) in the four weeks before the blood sample
was collected. Patients who died or were discharged from
the ICU within four hours of admission were also ex-
cluded because data collection was difficult for these pa-
tients. The Shanghai Jiaotong University Xinhua Hospital
Ethics Committee approved the study and waived the
requirement for informed consent, because this was an
observational study and all laboratory indices observed
were commonly measured for all patients in our ICU
department.
Definition of acute kidney injury
The patients were diagnosed as having AKI by using the
stage 1 AKI criteria of the Acute Kidney Injury Network
(AKIN) classification: new-onset of at least 1.5-fold in-
crease or ≥0.3 mg/dL (26.5 umol/L) increment of SCr
from baseline. If the preadmission Scr was available, wedefined baseline creatinine by using the following rules
ranked in descending order of preference: 1) the lowest
value between three and 365 days preadmission; 2) the
lower value of either preadmission Scr within three days
preadmission or the lowest Scr measurement in seven
days after admission to the ICU, if it was less than the
initial creatinine on entry to the ICU; and 3) the lowest
value of preadmission Scr within three days. If the value
of 2) and 3) were greater than the initial creatinine on
entry to the ICU or if the preadmission value was unavail-
able, then the lower value of either the initial creatinine
on entry to the ICU or the lowest pCr measurement in
seven days was used. We did not use the Modification of
Diet in Renal Disease (MDRD) formula to back-calculate
baseline creatinine because using this method to estimate
baseline creatinine would result in an overestimation of
the prevalence of AKI [28].
Clinical data and laboratory methods
We prospectively collected each patient's demographic
and clinical characteristics, including the Acute Physiolgy
and Chronic Health Evaluation II (APACHE-II) score
(which can range from 0 to 71, with higher scores indicat-
ing more severe illness). Serum Cysc, creatinine, glucose,
lactate, electrolytes and albumin levels were measured
using a Hitachi 7600–120 analyzer (Hitachi, Tokyo,
Japan). The analytical range of Cysc in the laboratory
of our hospital is 0.4 to 7.5 mg/L. The reported total
coefficients of variation are 4.2% at mean concentrations
0.6 mg/L and 3.8% at 1.4 mg/L, respectively. Thyroid
hormones, including free triiodothyronine (FT3), free
thyroxine (FT4), total triiodothyronine (TT3), total thy-
roxine (TT4) and thyroid-stimulating hormone (TSH),
were measured using the ADVIA Centaur immunoassay
system (Siemens Healthcare Diagnostics Inc, Tarrytown,
NY, USA). Reverse triiodothyronine (rT3) level was mea-
sured using the Maglumi 1000 Analyzer chemilumines-
cence immunoassay system (SNIBE Co, Ltd, Guandong,
China). Serum C-reactive protein (CRP) levels were mea-
sured using the QuikRead CRP test kit (Orion Diagnostica,
Espoo, Finland). We calculated the estimated glomerular
filtration rate (eGFR) by using the abbreviated MDRD
study equation. Blood samples were collected from all eli-
gible patients when they were admitted to the ICU.
Statistical analysis
Continuous variable and categorical variables were pre-
sented as mean value ± SD and precent, respectively. Bi-
variate correlation analysis was utilized to examine the
association between two variables. Multivariate linear re-
gression was performed to search for factors independ-
ently associated with Cysc. A criterion of P <0.05 for
entry and P ≥0.10 for removal was imposed in this pro-
cedure. We divided FT4 into quartiles and compared
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results with analysis of variance for continuous variables
and chi-square or Fisher’s exact tests for categorical vari-
ables. Receiver operator characteristic (ROC) curve was
used to examine the performance of Cysc to detect AKI.
The curve represented a plot of sensitivity versus 1-
specificity. The area under the curve (AUC) was derived
from the ROC curve. The differences between AUC were
tested by Hanley – McNeil methods [29]. A statistically
derived value, based on the Youden index16, maximizing
the sum of the sensitivity and specificity was used to de-
fine the optimal cut-off value. A two-sided P value <0.05
was considered to indicate statistical significance. All ana-
lyses were performed with SPSS 13.0 software.
Results
Base-line characteristics and base-line factors related to
Cysc
Cysc and thyroid hormones were missed in 12 patients.
Those patients were excluded from the study. A total of
446 patients were screened for eligibility in this analysis.
The mean age was 69.07 ± 15.58 years and 58.3% were
men. Mean Apache-II score was 15.46 ± 7.34. On entry
to the ICU, 114 (25.6%) had a clinical diagnosis of AKI.
A total of 56 patients died during their ICU stay. In
Table 1, bivariate correlation analysis shows that a higher
level of Cysc was associated with older age, higher level
of baseline Scr and current Scr, higher Apache-II score
and lower level of albumin. In addition, there was a
negative association between Cysc and TT3 as well as




Current Scr (umol/L) 0.684 0.000
Baseline Scr (umol/L) 0.562 0.000
Sex 0.027 0.568
Age (years) 0.380 0.000
Albumin (g/L) −0.230 0.000
TT3 (nmol/L) −0.099 0.036
TT4 (nmol/L) 0.005 0.916
FT3 (pmol/L) −0.180 0.000
FT4 (pmol/L) 0.098 0.039
TSH (IU/mL) 0.168 0.054
rT3 (nmol/L) −0.005 0.911
APACHE-II score 0.429 0.000
APACHE II score, Acute Physiology and Chronic Health Evaluation II score;
Baseline Scr, baseline serum creatinine; Current Scr, serum creatinine on the
entry to ICU; FT3, free triiodothyronine; FT4, free thyroxine; rT3, reverse
triiodothyronine; TSH, thyroid-stimulating-hormone; TT3, total triiodothyronine;
TT4, total thyroxine.multivariate linear regression (Table 2), age (standardized
beta = 0.128, P <0.0001), baseline Scr level (standardized
beta = 0.290, P <0.0001), current Scr (standardized beta =
0.453, P <0.0001), albumin (standardized beta = −0.086,
P = 0.006), and FT4 (standardized beta = 0.062, P = 0.039)
were related to Cysc.
Differences in clinical and laboratory characteristics
among the quartiles of FT4 are listed in Table 3. Patients
in the higher quartiles of FT4 tended to be older and
had higher levels of albumin, TT4 and FT3, and a low
level of TSH. However, there was no significant differ-
ence among the four quartiles in other clinical and la-
boratory characteristics, including sex, level of baseline
Scr, current Scr, Cysc, TT3, rT3, APACHE-II score as
well as the prevalence of AKI.Association between thyroid hormones and APACHE-II
scores
Among the thyroid hormones, only FT4 was not related to
APACHE-II scores (P = 0.219). FT3 (r = −0.363, P <0.001),
TT3 (r = −0.138, P <0.001), TT4 (r = −0.338, P <0.001),
TSH (r = −0.133, P = 0.005) and rT3 (r = −0.205, P <0.001)
were all correlated with APACHE-II scores.Association between Cysc and AKI in patients with
different levels of FT4
To evaluate the impact of FT4 on the accuracy of Cysc
in the diagnosis of AKI, a ROC curve was drawn in each
quartile of FT4 (Figure 1). The AUC was calculated as
0.712 in quartile I, 0.754 in quartile II, 0.829 in quartile
III and 0.797 in quartile IV (Table 4). There was no sig-
nificant difference in AUC between any two groups. The
optimal cut-off value of Cysc for diagnosing AKI increased
across FT4 quartiles (quartile I and quartile II = 1.15 mg/L,






Current Scr (umol/L) 0.486 0.000
Baseline Scr (umol/L) 0.290 0.000
Age (years) 0.128 0.000
Albumin (g/L) −0.086 0.006
FT4 (pmol/L) 0.062 0.039
Constant 0.291 (Unstandardized) 0.109
aIndependent variables included age, sex, baseline Scr, current Scr, albumin,
TT3, TT4, FT3, FT4, TSH. Variables not listed in the table were removed from
the stepwise analysis. Adjusted R square 0.627. Baseline Scr, baseline serum
creatinine; Current Scr, serum creatinine on the entry to ICU; FT3, free
triiodothyronine; FT4, free thyroxine; rT3, reverse triiodothyronine; TSH,
thyroid-stimulating-hormone; TT3, total triiodothyronine; TT4, total thyroxine.
Table 3 Baseline clinical and laboratory characteristics by quartile of FT4
I II III IV P
Number 111 111 112 112 /
Age (years) 65.2 ± 16.7 69.4 ± 15.6 71.3 ± 15.1 70.3 ± 14.4 0.020
Men, Number (%) 65 (58.6) 67 (60.4) 72 (64.3) 56 (50.0) 0.171
APACHE-II score (points) 15.6 ± 7.3 15.1 ± 7.9 14.9 ± 6.7 16.3 ± 7.4 0.524
Baseline Scr (umol/L) 80.0 ± 45.9 80.0 ± 39.0 86.6 ± 46.4 84.0 ± 48.7 0.636
Current Scr (umol/L) 98.2 ± 89.4 100.7 ± 61.5 108.1 ± 79.7 106.8 ± 76.1 0.741
Cysc (mg/L) 1.23 ± 0.65 1.23 ± 0.51 1.32 ± 0.67 1.35 ± 0.79 0.354
Albumin (g/L) 32.7 ± 4.7 35.0 ± 6.1 35.1 ± 5.0 35.4 ± 5.5 0.000
TT3 (nmol/L) 0.83 ± 0.39 0.94 ± 0.34 0.89 ± 0.29 0.90 ± 0.36 0.109
TT4 (nmol/L) 72.04 ± 28.93 89.17 ± 23.00 90.03 ± 20.98 94.32 ± 24.29 0.000
FT3 (pmol/L) 3.04 ± 0.62 3.27 ± 0.54 3.42 ± 0.59 3.66 ± 0.92 0.000
FT4 (pmol/L) 11.93 ± 1.54 14.47 ± 0.53 16.14 ± 0.50 19.58 ± 3.17 0.000
TSH (IU/mL) 3.87 ± 16.16 1.26 ± 1.03 1.70 ± 1.84 1.14 ± 1.05 0.044
rT3 (nmol/L) 0.49 ± 0.21 0.54 ± 0.21 0.54 ± 0.24 0.57 ± 0.27 0.113
AKI (Number, %) 24 (21.6) 26 (23.4) 36 (32.1) 28 (25.0) 0.292
Quartile cut points for FT4 were 13.49, 15.38 and 17.07 pmol/L, continuous variables were compared with one-way ANOVA, and dichotomous variables were
compared with the chi-square test. ANOVA, analysis of variance; APACHE II score, Acute Physiology and Chronic Health Evaluation II score; Baseline Scr, baseline
serum creatinine; Current Scr, serum creatinine on the entry to ICU; Cysc, Cystatin C; FT3, free triiodothyronine; FT4, free thyroxine; rT3, reverse triiodothyronine;
TSH, thyroid-stimulating-hormone; TT3, total triiodothyronine; TT4, total thyroxine.
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In this prospective study, we first assessed the impact of
thyroid function on the accuracy of Cysc in the diagnosis
of AKI in ICU patients. The primary findings of this
study are as follows: (1) FT4 was the only index among
thyroid hormones that was not correlated with APACHE-
II score and still related to the Cysc level after adjusting
for several confounding factors; (2) there was no signifi-
cant difference in the diagnostic performance of Cysc
among patients with different FT4 levels; and (3) the opti-
mal cut-off value of Cysc in diagnosing AKI increased as
FT4 increased.
Previous studies have shown that some thyroid hor-
mones might be confounded by critical illness and a
low FT3 level was correlated with the severity of morbid-
ity and the outcomes of patients in ICUs [30,31]. Our
present study also confirmed the negative association be-
tween FT3 level and APACHE-II score. As we know, the
severity of illness score was positively associated with the
risk of AKI as well as the level of Cysc, and thus FT3 was
inversely related to Cysc. However, the level of FT4 was
the only index among thyroid hormones that was not
related to the APACHE-II score in this study. This indi-
cated that FT4 was less affected by the severity of illness
and could reflect a stable state of thyroid hormones as
compared with other indices of thyroid hormones. So,
FT4 can directly reflect the stimulating effect of thyroid
hormones on Cysc and FT4 was positively related to Cysc.
In fact, FT4 was the only index independently correlated
with Cysc. Based on these results, we chose FT4 asthe representative variable to assess the impact of thyroid
function on the accuracy of Cysc in the diagnosis of AKI
in ICU patients.
Cysc used to be considered less subject to the non-
renal variables that impact Scr. However, more recent
studies [18-24,32] have found that several factors are as-
sociated with higher Cysc in noncritically ill patients, in-
cluding older age, male sex, current smoking status,
elevated CRP levels as well as thyroid hormones. How-
ever, the factors associated with the Cysc level were not
well defined in critically ill patients. In a study of 85 ICU
patients, the investigator reported that the Cysc level
was not affected by low T3 or T3/T4 syndrome [6]. In
contrast with this study, we found that Cysc level was
not only associated with both baseline Scr and current
Scr levels, but also is related to age, and levels of albu-
min and FT4 in ICU patients.
Results relating to the diagnostic accuracy of Cysc in
detecting AKI have been conflicting in previous studies.
The AUC for Cysc ranged from 0.55 to 0.99 across dif-
ferent studies [16]. Some previous studies have found
that thyroid hormones were associated with Cysc level
both in vitro [18,19] and in vivo [20-24], but whether the
thyroid function could affect the performance of Cysc to
identify AKI was never investigated before. Our present
study showed that the difference of AUC among differ-
ent FT4 quartiles did not reach statistical significance.
Although thyroid hormones could stimulate the produc-
tion of Cysc at baseline as well as the progress of AKI
after a critical illness, the acute decrease of GFR during
Figure 1 Receiver operating characteristic curves for Cysc in quartile I (A), quartile II (B), quartile III (C) and quartile IV (D).
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increment of Cysc from baseline. This may be the rea-
son. However, the optimal cut-off value of Cysc in the
diagnosis of AKI increased with increasing FT4 quartile
is an interesting finding. This result indicates that FT4
might stimulate Cysc production and, thus, affect the
absolute value of Cysc and the optimal cut-off value ofTable 4 Performance of Cysc in diagnosing AKI by
quartile of FT4
AUC ROC 95% CI Cut-off Sensitivity Specificity
I 0.712 ± 0.066 0.582-0.841 1.15 0.708 0.667
II 0.754 ± 0.059 0.638-0.870 1.15 0.808 0.635
III 0.829 ± 0.041 0.748-0.910 1.35 0.694 0.816
IV 0.797 ± 0.049 0.700-0.893 1.45 0.643 0.833
Quartile I versus Quartile II Z = 0.474, P = 0.318; Quartile I versus Quartile III
Z = 1.506, P = 0.066; Quartile I versus Quartile IV Z = 1.034, P = 0.151; Quartile II
versus Quartile III Z = 1.044, P = 0.148; Quartile II versus Quartile IV Z = 0.561,
P = 0.288]. Quartile III versus Quartile IV Z = 0.501, P = 0.308. AUC ROC, area
under the receiver operating characteristic curve; CI, confidence interval.Cysc in the diagnosis of AKI. This result may be one of
the explanations fpr a wide range of optimal cut-off
values of Cysc in detecting AKI in previous studies [16].
It also should be taken into consideration when using
Cysc to identify AKI in clinical settings.
Several limitations to our study exist. First, we used
Cysc to diagnose rather than predict AKI. We could not
exclude the possibility that some non-AKI patients pro-
gressed to AKI after their entry into the ICU. However,
whether Cysc could serve as an early biomarker of AKI re-
mains uncertain. Second, because some unknown non-
GFR determinants of Cysc may exist, the relationship
between Cysc and thyroid hormones would be changed if
adjusting for those confounding factors.
Conclusions
In this large-scale study of unselected ICU patients, we
found that FT4 was the only index among thyroid hor-
mones that was not correlated with APACHE-II score
and still related to Cysc level after adjusting for several
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impact on the diagnostic accuracy of Cysc to detect AKI
in ICU patients. However, the optimal cut-off value of
Cysc to detect AKI could be affected by thyroid function.
Key messages
 FT4 was the only index among thyroid hormones
that was not correlated with APACHE-II score and
still related to Cysc level after adjusting for several
confounding factors.
 There was no significant impact of thyroid function
on the diagnostic accuracy of Cysc to detect AKI in
ICU patients.
 The optimal cut-off value of Cysc to detect AKI
could be affected by thyroid function.
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